Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.865
+0.1551.78%
Volume:95.91M
Turnover:839.32M
Market Cap:102.14B
PE:22.32
High:8.890
Open:8.580
Low:8.520
Close:8.710
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.83
T/O Rate:0.83%
Dividend:0.34
Dividend Rate:3.80%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.32
PE(LYR):22.32
PS:2.79

Loading ...

CSPC Pharma's Sirolimus Drug Application Accepted in China

MT Newswires Live
·
Jul 28

Movement Alert|CSPC PHARMA Rises 3.86% in Regular Trading, Interim Profit Forecast Surges as Antidepressant Drug Phase III Trial Hits Primary Endpoint

Market Focus
·
Jul 28

Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street

Stock News
·
Jul 28

Cspc Pharmaceutical Says Phase III Trial of Ha1406 Meets Primary Endpoint

Reuters
·
Jul 27

CSPC PHARMA's Injectable Sirolimus (Albumin-Bound) New Drug Application Accepted by China's NMPA

Stock News
·
Jul 27

CSPC Pharma: Ammoxetine (HA1406) Clears Phase III with Statistically Significant Efficacy in Depression

Bulletin Express
·
Jul 27

CSPC Says China NMPA Accepts Sirolimus Albumin-bound Injection Filing, Grants Priority Review

Reuters
·
Jul 27

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Sirolimus for Injection (Albumin-Bound)

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical - Phase Iii Trial of Ha1406 for Depression Meets Primary Endpoint with Statistical Significance

THOMSON REUTERS
·
Jul 27

CSPC PHARMA (01093) Issues Positive Profit Alert, Expects Significant Interim Net Profit Growth to Around RMB 5.9-6.2 Billion

Stock News
·
Jul 27

CSPC Innovation Pharma, CSPC Pharmaceutical Group Unit, Forecasts H1 Net Profit at 1.18 Billion-1.36 Billion Yuan

Reuters
·
Jul 27

CSPC Pharmaceutical - Expects H1 2026 Profit Attributable to Owners of Rmb5.9 Bln–RMB6.2 Bln

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical - Expected Result Due to Significant Increase in Licence Fee Income, Others in Hy

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical Group Stock Falls 2.9% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jul 27

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.31 From HK$12.04, Keeps at Buy

MT Newswires Live
·
Jul 27

Movement Alert|CSPC PHARMA Declines 3.16% in Regular Trading, Trading at HK$8.3

Market Focus
·
Jul 27

CSPC Pharmaceutical Group (SEHK:1093) Could Be 115% Below Fair Value Following Drug Approval

Simply Wall St.
·
Jul 27

Hong Kong Stock Market Analysis: ChangXin IPO Pressure Weighs, Agricultural Inflation Risks Boost Related Stocks

Stock News
·
Jul 24

CSPC Pharma Gains NMPA Approval for Once-Monthly Paliperidone Palmitate Injection to Treat Schizophrenia

Bulletin Express
·
Jul 24

CSPC Pharma's Paliperidone Palmitate Injection Receives Market Approval

Stock News
·
Jul 24